Pesquisa | SciELO

Abstract Objective To develop the second evidence-based Brazilian Society of Rheumatology consensus for diagnosis and treatment of lupus nephritis (LN). Methods Two methodologists and 20 rheumatologists from Lupus Comittee of Brazilian Society of Rheumatology participate in the development of this guideline. Fourteen PICO questions were defined and a systematic review was performed. Eligible randomized controlled trials were analyzed regarding complete renal remission, partial renal remission, serum creatinine, proteinuria, serum creatinine doubling, progression to end-stage renal disease, renal relapse, and severe adverse events (infections and mortality). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to develop these recommendations. Recommendations required ≥82% of agreement among the voting members and were classified as strongly in favor, weakly in favor, conditional, weakly against or strongly against a particular intervention. Other aspects of LN management (diagnosis, general principles of treatment, treatment of comorbidities and refractory cases) were evaluated through literature review and expert opinion. Results All SLE patients should undergo creatinine and urinalysis tests to assess renal involvement. Kidney biopsy is considered the gold standard for diagnosing LN but, if it is not available or there is a contraindication to the procedure, therapeutic decisions should be based on clinical and laboratory parameters. Fourteen recommendations were developed. Target Renal response (TRR) was defined as improvement or maintenance of renal function (±10% at baseline of treatment) combined with a decrease in 24-h proteinuria or 24-h UPCR of 25% at 3 months, a decrease of 50% at 6 months, and proteinuria < 0.8 g/24 h at 12 months. Hydroxychloroquine should be prescribed to all SLE patients, except in cases of contraindication. Glucocorticoids should be used at the lowest dose and for the minimal necessary period. In class III or IV (±V), mycophenolate (MMF), cyclophosphamide, MMF plus tacrolimus (TAC), MMF plus belimumab or TAC can be used as induction therapy. For maintenance therapy, MMF or azathioprine (AZA) are the first choice and TAC or cyclosporin or leflunomide can be used in patients who cannot use MMF or AZA. Rituximab can be prescribed in cases of refractory disease. In cases of failure in achieving TRR, it is important to assess adherence, immunosuppressant dosage, adjuvant therapy, comorbidities, and consider biopsy/rebiopsy. Conclusion This consensus provides evidence-based data to guide LN diagnosis and treatment, supporting the development of public and supplementary health policies in Brazil. evidencebased evidence LN. . (LN) 2 guideline performed remission doubling endstage end stage disease relapse infections mortality. mortality mortality) Assessment GRADE (GRADE 82 ≥82 favor conditional intervention diagnosis, (diagnosis opinion involvement but procedure parameters developed TRR (TRR ±10% 10 (±10 24h 24 25 months 50 08 0 8 0. g24 g g/2 1 period ±V, V ±V , (±V) MMF, (MMF) cyclophosphamide TAC, (TAC) therapy AZA (AZA adherence dosage biopsyrebiopsy rebiopsy biopsy/rebiopsy Brazil (LN ≥8 ±10 (±1 5 g2 g/ (±V (MMF (TAC ≥ ±1 (± ± (

https://doi.org/10.1186/s42358-024-00386-8

Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Pileggi, Gecilmara Salviato

; Ferreira, Gilda Aparecida

; Gomides Reis, Ana Paula Monteiro

; Reis Neto, Edgard Torres

; Abreu, Mirhelen Mendes

; Albuquerque, Cleandro Pires

; Araújo, Nafice Costa

; Bacchiega, Ana Beatriz

; Bianchi, Dante Valdetaro

; Bica, Blanca

; Bonfa, Eloisa Duarte

; Borba, Eduardo Ferreira

; Brito, Danielle Christinne Soares Egypto

; Duarte, Ângela Luzia Branco Pinto

; Santo, Rafaela Cavalheiro Espírito

; Fernandes, Paula Reale

; Guimarães, Mariana Peixoto

; Gomes, Kirla Wagner Poti

; Kakehasi, Adriana Maria

; Klumb, Evandro Mendes

; Lanna, Cristina Costa Duarte

; Marques, Claudia Diniz Lopes

; Monticielo, Odirlei André

; Mota, Licia Maria Henrique

; Munhoz, Gabriela Araújo

; Paiva, Eduardo Santos

; Pereira, Helena Lucia Alves

; Provenza, José Roberto

; Ribeiro, Sandra Lucia Euzébio

; Rocha Junior, Laurindo Ferreira

; Sampaio, Camila Santana Justo Cintra

; Sampaio, Vanderson Souza

; Sato, Emília Inoue

; Skare, Thelma

; de Souza, Viviane Angelina

; Valim, Valeria

; Lacerda, Marcus Vinícius Guimarães

; Xavier, Ricardo Machado

; Pinheiro, Marcelo Medeiros

Advances in Rheumatology

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

2021, Volume 61 elocation 60

Resumo: En | Texto: En | PDF: En

Abstract Background: There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak. Our aim was to compare the occurrence of COVID-19 between rheumatic disease patients on hydroxychloroquine with individuals from the same household not taking the drug during the first 8 weeks of community viral transmission in Brazil. Methods: This baseline cross-sectional analysis is part of a 24-week observational multi-center study involving 22 Brazilian academic outpatient centers. All information regarding COVID-19 symptoms, epidemiological, clinical, and demographic data were recorded on a specific web-based platform using telephone calls from physicians and medical students. COVID-19 was defined according to the Brazilian Ministry of Health (BMH) criteria. Mann-Whitney, Chi-square and Exact Fisher tests were used for statistical analysis and two binary Final Logistic Regression Model by Wald test were developed using a backward-stepwise method for the presence of COVID-19. Results: From March 29th to May 17st, 2020, a total of 10,443 participants were enrolled, including 5166 (53.9%) rheumatic disease patients, of whom 82.5% had systemic erythematosus lupus, 7.8% rheumatoid arthritis, 3.7% Sjögren’s syndrome and 0.8% systemic sclerosis. In total, 1822 (19.1%) participants reported flu symptoms within the 30 days prior to enrollment, of which 3.1% fulfilled the BMH criteria, but with no significant difference between rheumatic disease patients (4.03%) and controls (3.25%). After adjustments for multiple confounders, the main risk factor significantly associated with a COVID-19 diagnosis was lung disease (OR 1.63; 95% CI 1.03-2.58); and for rheumatic disease patients were diagnosis of systemic sclerosis (OR 2.8; 95% CI 1.19-6.63) and glucocorticoids above 10 mg/ day (OR 2.05; 95% CI 1.31-3.19). In addition, a recent influenza vaccination had a protective effect (OR 0.674; 95% CI 0.46-0.98). Conclusion: Patients with rheumatic disease on hydroxychloroquine presented a similar occurrence of COVID-19 to household cohabitants, suggesting a lack of any protective role against SARS-CoV-2 infection. Trial registration Brazilian Registry of Clinical Trials (ReBEC; RBR - 9KTWX6).

https://doi.org/10.1186/s42358-021-00217-0 22 downloads

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Reis Neto, Edgard Torres dos

; Kakehasi, Adriana Maria

; Pinheiro, Marcelo de Medeiros

; Ferreira, Gilda Aparecida

; Marques, Cláudia Diniz Lopes

; Mota, Licia Maria Henrique da

; Paiva, Eduardo dos Santos

; Pileggi, Gecilmara Cristina Salviato

; Sato, Emília Inoue

; Reis, Ana Paula Monteiro Gomides

; Xavier, Ricardo Machado

; Provenza, José Roberto

Advances in Rheumatology

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

2020, Volume 60 elocation 32

Resumo: En | Texto: En | PDF: En

Abstract Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.

https://doi.org/10.1186/s42358-020-00134-8 2393 downloads

Psychoanalytic psychotherapy improves quality of life, depression, anxiety and coping in patients with systemic lupus erythematosus: a controlled randomized clinical trial
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Conceição, Céu Tristão Martins

; Meinão, Ivone Minhoto

; Bombana, José Atilio

; Sato, Emília Inoue

Advances in Rheumatology

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

2019, Volume 59 elocation 4

Resumo: En | Texto: En | PDF: En

Abstract Background: Systemic Lupus Erythematosus (SLE) is an autoimmune disease which impairs the quality of life. The objective of study was to evaluate the effectiveness of Brief Group Psychoanalytic Psychotherapy to improve quality of life, depression, anxiety and coping strategies in SLE patients. Methods: In a randomized clinical trial, 80 female SLE patients were allocated into two groups: therapy group (n = 37) and control group (n =43). Therapy group (TG) attended weekly psychotherapy sessions for 20 weeks; control group (CG) remained on a waiting list. Both groups received standard medical care. Questionnaires and scales were applied by blinded evaluators at baseline (T1) and after 20 weeks (T2): Socioeconomic Status, SLE International Collaborating Clinic/American College of Rheumatology-Damage Index, SLE International Disease Activity, SLE Specific Symptom Checklist, SLE Quality of life, Hospital Anxiety Depression Scale, Coping Strategies Inventory. Intent to treat intra- and inter-group analysis was performed for all variables in T1 and T2 using Qui-square, t-Student, Mann-Whitney and Wilcoxon tests. Analysis of Variance was used to compare categorical variables overtime. P < 0.05 was considered significant. Results: The mean age of patients was 42 years; 54% were white, with mean disease duration of years 12. At baseline, both groups were homogeneous in all variables, including medications. After 20 weeks of psychotherapy TG was significantly different from CG, with lower frequency of symptoms (p = 0.001), lower level of anxiety (p = 0.019) and depression (p = 0.022), better index in five of six domains of quality of life scale (p ≤ 0.005), including total SLEQOL (p < 0.001) and with higher positive planful problem solving strategy (p = 0.017). No change in disease activity score was observed in both groups. Conclusions: Psychoanalytic psychotherapy was effective to improve many domains of quality of life and one positive coping skill and to reduce SLE symptoms, anxiety and depression levels. Brief group psychotherapy can be a useful tool to complement medical care in SLE patients. Trial registration: Number NCT01840709.

https://doi.org/10.1186/s42358-019-0047-y 721 downloads

Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Faludi, André Arpad

; Izar, Maria Cristina de Oliveira

; Saraiva, José Francisco Kerr

; Chacra, Ana Paula Marte

; Bianco, Henrique Tria

; Afiune Neto, Abrahão

; Bertolami, Adriana

; Pereira, Alexandre C.

; Lottenberg, Ana Maria

; Sposito, Andrei C.

; Chagas, Antonio Carlos Palandri

; Casella Filho, Antonio

; Simão, Antônio Felipe

; Alencar Filho, Aristóteles Comte de

; Caramelli, Bruno

; Magalhães, Carlos Costa

; Negrão, Carlos Eduardo

; Ferreira, Carlos Eduardo dos Santos

; Scherr, Carlos

; Feio, Claudine Maria Alves

; Kovacs, Cristiane

; Araújo, Daniel Branco de

; Magnoni, Daniel

; Calderaro, Daniela

; Gualandro, Danielle Menosi

; Mello Junior, Edgard Pessoa de

; Alexandre, Elizabeth Regina Giunco

; Sato, Emília Inoue

; Moriguchi, Emilio Hideyuki

; Rached, Fabiana Hanna

; Santos, Fábio César dos

; Cesena, Fernando Henpin Yue

; Fonseca, Francisco Antonio Helfenstein

; Fonseca, Henrique Andrade Rodrigues da

; Xavier, Hermes Toros

; Mota, Isabela Cardoso Pimentel

; Giuliano, Isabela de Carlos Back

; Issa, Jaqueline Scholz

; Diament, Jayme

; Pesquero, João Bosco

; Santos, José Ernesto dos

; Faria Neto, José Rocha

; Melo Filho, José Xavier de

; Kato, Juliana Tieko

; Torres, Kerginaldo Paulo

; Bertolami, Marcelo Chiara

; Assad, Marcelo Heitor Vieira

; Miname, Márcio Hiroshi

; Scartezini, Marileia

; Forti, Neusa Assumpta

; Coelho, Otávio Rizzi

; Maranhão, Raul Cavalcante

; Santos Filho, Raul Dias dos

; Alves, Renato Jorge

; Cassani, Roberta Lara

; Betti, Roberto Tadeu Barcellos

; Carvalho, Tales de

; Martinez, Tânia Leme da Rocha

; Giraldez, Viviane Zorzanelli Rocha

; Salgado Filho, Wilson

Arquivos Brasileiros de Cardiologia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Ago 2017, Volume 109 Nº 2 Páginas 1 - 76

Resumo: Pt | Texto: Pt | PDF: Pt

https://doi.org/10.5935/abc.20170121 199102 downloads

Consenso de lúpus eritematoso sistêmico
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Borba, Eduardo Ferreira

; Latorre, Luiz Carlos

; Brenol, João Carlos Tavares

; Kayser, Cristiane

; Silva, Nilzio Antonio da

; Zimmermann, Adriana Fontes

; Pádua, Paulo Madureira de

; Costallat, Lilian Tereza Lavras

; Bonfá, Eloísa

; Sato, Emília Inoue

Revista Brasileira de Reumatologia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Ago 2008, Volume 48 Nº 4 Páginas 196 - 207

Resumo: Pt | Texto: Pt | PDF: Pt

190478 downloads Citado 10 vezes em SciELO

Tratamento da arterite de Takayasu
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Souza, Alexandre Wagner Silva de

; Neves, Raissa Maria Sampaio

; Oliveira, Kathia Regina

; Sato, Emília Inoue

Revista Brasileira de Reumatologia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Jun 2006, Volume 46 Supl. 1 Páginas 2 - 7

Resumo: Pt En | Texto: Pt En | PDF: Pt | PDF: En

A arterite de Takayasu (AT) é uma vasculite granulomatosa crônica que envolve a aorta e seus principais ramos. A monitoração da atividade da doença e o melhor esquema terapêutico ainda têm sido um desafio para todos os que tratam estes pacientes. Corticosteróides e imunossupressores vêm sendo utilizados na prática clínica diária com resultados nem sempre animadores. Apesar de não haver estudos controlados que abordem o tratamento da AT, diferentes estudos observacionais descrevem a resposta de pacientes com AT ao uso de corticosteróides, metotrexato (MTX), azatio-prina e ciclofosfamida. Após a introdução da terapia biológica, novas perspectivas têm surgido para os pacientes com AT refratários aos esquemas terapêuticos tradicionais.

Takayasus’s arteritis is a chronic granulomatous vasculitis involving the aorta and its main branches. Monitoring disease activity and the choice for the best therapy has been major challenger faced by all physicians who treat these patients. Corticosteroids and immunosuppressive therapy have been used in daily medical practice, but results have not always been encouraging. Although there are no controlled studies evaluating the treatment of Takayasu’s arteritis, observational studies have described the response to the use of corticosteroids, methotrexate, azathioprine and cyclophosphamide. The emerging of biological therapy has brought new perspective for Takayasu’s patients who are refractory to conventional therapy.

26039 downloads

Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Souza, Alexandre Wagner Silva de

; Hatta, Francisca Satomi

; Miranda Jr., Fausto

; Sato, Emília Inoue

Sao Paulo Medical Journal

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Mai 2005, Volume 123 Nº 3 Páginas 137 - 142

Resumo: Pt En | Texto: Pt En | PDF: Pt | PDF: En

CONTEXTO E OBJETIVO: Doença aterosclerótica é importante causa de morbidade e mortalidade em pacientes com lúpus eritematoso sistêmico. Não há estudos que verifiquem a prevalência de aterosclerose em carótidas nesses pacientes no Brasil. O objetivo deste trabalho foi estimar a prevalência de aterosclerose em carótidas em pacientes com lúpus e em controles, e avaliar associação entre fatores de risco e aterosclerose em carótidas. TIPO DE ESTUDO E LOCAL: Estudo transversal na: Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brasil. MÉTODOS: Foi utilizado o ultra-som modo B de carótidas em 82 mulheres com lúpus eritematoso sistêmico e em 62 controles. A idade média das pacientes foi de 34,0 anos (variação 16-65) e dos controles foi de 35,7 anos (variação 18-64). Placa aterosclerótica foi definida como área distinta de hiperecogenicidade ou como área focal de protrusão da parede para o lúmen do vaso. Foram pesquisados fatores de risco para doença coronária e variáveis relacionadas ao lúpus. RESULTADOS: 50% dos pacientes e 29% dos controles apresentaram placas em carótidas (p = 0,011). Idade mais avançada, maior tempo de lúpus, maior pontuação do escore Systemic Lupus International Collaborating Clinics, maiores níveis de lipoproteína de baixa densidade, maior freqüência de diabetes, falência ovariana precoce, obesidade e história familiar de doença coronariana foram encontrados em pacientes com placas de carótidas. Pacientes com placas em carótidas tiveram menor média de idade em relação às controles com placas. Fatores de risco associados a placas em carótidas foram diagnóstico de lúpus (razão de chances: 4,74; intervalo de confiança de 95%: 1,83 a 12,27), obesidade (razão de chances: 6,16; intervalo de confiança de 95%: 1,84 a 20,64), idade avançada (razão de chances: 1,12; intervalo de confiança de 95%: 1,07 a 1,17), maior escore Systemic Lupus International Collaborating Clinics (razão de chances: 1,69; intervalo de confiança de 95%: 1,31 a 2,52) e maior tempo de lúpus (razão de chances: 1,65; intervalo de confiança de 95%: 1,06 a 2,56). CONCLUSÃO: Pacientes jovens com lúpus apresentam maior prevalência de aterosclerose de carótidas. O diagnóstico de lúpus eritematoso sistêmico foi fator de risco para aterosclerose de carótidas.

CONTEXT AND OBJECTIVE: Atherosclerotic disease is an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients. No previous study has estimated carotid disease prevalence in such patients in Brazil. The aim was to evaluate the prevalence of atherosclerotic plaque in carotid arteries, in SLE patients and controls, and to verify possible associations between risk factors and carotid plaque. DESIGN AND SETTING: Cross-sectional study, at Universidade Federal de São Paulo - Escola Paulista de Medicina. METHODS: Carotid plaque prevalence was assessed by B-mode ultrasound in 82 female SLE patients of mean age 34.0 years and 62 controls of mean age 35.7 years. Plaque was defined as a distinct area of hyperechogenicity and/or focal protrusion of the vessel wall into the lumen. Risk factors for coronary disease and SLE-related variables were determined. RESULTS: 50% of patients and 29% of controls presented carotid plaque. Older age, longer disease duration, higher Systemic Lupus International Collaborating Clinics (SLICC) score, higher levels of low-density lipoprotein and greater diabetes, obesity, premature ovarian failure and family history of coronary artery disease were found in patients with carotid plaque than in those without plaque. Patients with plaque were younger than controls with plaque. SLE diagnosis, obesity, older age, higher SLICC score and longer disease duration were independent risk factors for carotid plaque. CONCLUSION: Young patients with SLE present higher prevalence of carotid plaque than controls. SLE diagnosis was a significant risk factor for carotid atherosclerosis.

3587 downloads

Vena cava thrombosis associated with nephrotic syndrome in the puerperal gestational cycle
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Araújo, Maíta Poli

; Gonçalves, Carla

; Gonçalves, Roberta

; Braga Júnior, José Wilson Ramos

; Peterson, Thaís Vilela

; Atallah, Álvaro Nagib

; Sato, Emília Inoue

; Trevisani, Virgínia Fernandes Moça

Sao Paulo Medical Journal

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Jan 2001, Volume 119 Nº 1 Páginas 24 - 28

Resumo: Pt En | Texto: Pt En | PDF: Pt | PDF: En

CONTEXTO: A gestação é acompanhada de um estado fisiológico de hipercoagulabilidade. Fenômenos de Trombose podem ocorrer. OBJETIVO: Relatar um caso clínico envolvendo uma paciente que apresentava história importante de trombifilia familiar, e que desenvolveu trombose venosa profunda no membro inferior e trombose da veia cava durante o ciclo gravídico-puerperal, apresentando síndrome nefrótica como principal complicação. TIPO DE ESTUDO: Relato de caso.

CONTEXT: The puerperal gestational cycle is accompanied by a state of physiological hypercoagulability. Thromboembolic phenomena may occur at this time. OBJECTIVE: To report on a clinic case involving a patient that presented a family history of thromboembolism and developed deep vein thrombosis in a lower limb and vena cava thrombosis during the puerperal gestational cycle, displaying nephrotic syndrome as the main complication. DESIGN: Case report.

4274 downloads

Exibindo

itens por página

Página de 1 Próxima

Selecione um ou mais resultados

Todos Ordem alfabética

Resultados

Gráfico comparativo Download CSV

Visualizar estatísticas de

Enviar resultado

E-mail do(s) destinatários*

Utilize ; (ponto e vírgula) para mais de um e-mail.

Enviar por e-mail

Esta página

Registros selecionados

Todos os registros (max. 300)

Alterar remetente, assunto e comentários

Seu email

Assunto

Comentários

Alterar remetente, assunto e comentários

Exportar resultados

Formato de exportação:

RIS (para EndNote, ProCite, Reference Manager, RefWorks, Citavi, etc.)

BibTeX

Citação

CSV (para Excel, etc)

Exportar:

Esta página

Itens selecionados

Todos os registros (max. 2000)

Mostrar mais

Sem resultados

Não foram encontrados documentos para sua pesquisa

Glossário e ajuda para busca

Você pode enriquecer sua busca de uma forma muito simples. Use os índices de pesquisa combinados com os conectores (AND ou OR) e especifique cada vez mais sua busca.

Por exemplo, se você deseja buscar artigos sobre
casos de dengue no Brasil em 2015, use:
ti:dengue and publication_year:2015 and aff_country:Brasil

Veja abaixo a lista completa de índices de pesquisa que podem ser usados:

Cód. do Índice	Elemento
ti	título do artigo
au	autor
kw	palavras-chave do artigo
subject	assunto (palavras do título, resumo e palavras-chave)
ab	resumo
ta	título abreviado da revista (ex. Cad. Saúde Pública)
journal_title	título completo da revista (ex. Cadernos de Saúde Pública)
la	código do idioma da publicação (ex. pt - Português, es - Espanhol)
type	tipo do documento
pid	identificador da publicação
publication_year	ano de publicação do artigo
sponsor	financiador
aff_country	código do país de afiliação do autor
aff_institution	instituição de afiliação do autor
volume	volume do artigo
issue	número do artigo
elocation	elocation
doi	número DOI
issn	ISSN da revista
in	código da coleção SciELO (ex. scl - Brasil, col - Colômbia)
use_license	código da licença de uso do artigo

SciELO - Scientific Electronic Library Online
Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil
Email: scielo@scielo.org

Todo o conteúdo de www.scielo.org, exceto onde está identificado, está licenciado sob uma Licença Creative Commons.
saiba mais »